Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

l, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Isch
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... Wash. and VANCOUVER , ... OGXI ) announced today that it will report its ... 2015. Company management will host a conference call and ... an overview of financial results, clinical development programs and ... the webcast, log on to the Investor Relations page ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... MAY 22, 2012 ThermoGenesis Corp. (NASDAQ: ... the processing, storage and administration of cell therapies, today ... its AXP® AutoXpress® Platform (AXP) used for the processing ... initiate commercial activities in the country later this year. ...
... Holdings, Inc., the tenth largest workers, compensation insurer ... from Medco Health Solutions to Express Scripts as their ... analytics capabilities and insights generated by its team of ... waste and help improve outcomes for injured workers ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Accident Fund Holdings Aims to Improve Control of Drug Utilization and Quality of Care with Change in Pharmacy Benefit Manager 2
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for ... Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... for the annual Lollapalooza. This unique and unbelievably popular festival attracts the best ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The 2nd ... Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight On ... on cancer research between Methodist Healthcare, The West Clinic and The University of Tennessee ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and ... their social media profiles to better connect with the public. The agency website ... information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide ...
(Date:7/31/2015)... ... ... article published July 27 on My News LA, a fire that broke out ... fire department before it caused major damage throughout the building. The article also notes that ... a fire alarm system that tipped off fire fighters so they could arrive at the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic ... potential patients alike on various plastic surgery procedures including, but not limited to, ... popular dermatology procedures like Botox and fillers. , Staying up to date ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
... provides a better option as a treatment for empyema ... than another treatment// video-assisted thoracoscopic surgery. The researchers say ... results appear in the second issue for July 2006 ... Medicine, published by the American Thoracic Society. ...
... society representatives joined hands today to boost efforts by ... HIV/AIDS. // ,Headed by C Rangarajan, Chairman ... the 10-member independent commission on AIDS in Asia and ... developmental consequences of AIDS in the region and its ...
... has been pilloried back home for his moves to erode ... (AIIMS), his// ministry has been honoured for exemplary work in ... Society has hailed India's Ministry of Health and Family Welfare ... given it the award for Exemplary Leadership by a Government ...
... Female genital mutilation (FGM), excision of clitoris is practiced ... without the use of anesthetics. A senior doctor ... that is going on for generations, sorting out the ... published on bmj.com last month probes that the procedure ...
... anemia in the fetus, by measuring the velocity of ... is considered// absolutely safe, also because it is non-invasive, ... instead of amniocentesis. ,This was established ... Netherlands conducted a comparative study of the two methods ...
... removed a giant tumour weighing over 25 kilogram from the belly ... a patient in this age group. // ,The tumour ... extended from the uterus to the heart and was taken out ... the 'Himalayan Times'., ,"It is the largest tumour taken out ...
Cached Medicine News:Health News:Enzyme Urokinase Better Option In Empyema For Kids 2Health News:Enzyme Urokinase Better Option In Empyema For Kids 3Health News:Health Minister Ramadoss Honoured for his Exemplary Work 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Lyphochek Hypertension Markers Control is a trilevel control designed to monitor the performance of testing procedures for renin and other analytes associated with hypertension disorders....
Medicine Products: